Hepatic fibrosis improving agent

A liver fibrosis and improving agent technology, applied in the field of nutritional functional food and pharmaceuticals, can solve the problems that have not been mentioned

Active Publication Date: 2021-03-23
谢灵均 +1
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no relevant document showing that the combination of the two will produce synergistic effect
Moreover, the existing research is mainly aimed at suppressing inflammation, and there is no mention of the hydroxyproline content or the value of the type I collagen gene that indicates the state of fibrosis (non-patent paper 3)
[0009] Both involve the "anti-inflammatory effect" of the liver brought about by the administration of selenium, and there are no reports of "improvement" of fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hepatic fibrosis improving agent
  • Hepatic fibrosis improving agent
  • Hepatic fibrosis improving agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Rats were divided into groups of ten. The control group took thioacetamide aqueous solution (300mg / L) as drinking water, and continuously made rats take it for 10 weeks or 20 weeks; , continue to take polyprex zinc 200mg / day / kg for 10 weeks or continue to take zinc-selenium complex (Zn 45mg / day / kg, Se150μg / day / kg) for 10 weeks. The amount of zinc taken in by both is the same a day.

[0041] After the administration, the rats in the control group and the test group were killed, the livers were taken out, and hydroxyproline, an indicator of liver tissue fibrosis, was measured by absorbance using chloramine treated with hydrochloric acid and Ehrlich's reagent.

[0042] The content of hydroxyproline in the liver is as figure 1 shown. Improve the expression of fibrinolytic enzyme precursor proMMP-9 in liver fibrosis as shown in figure 2 shown. The results of the determination of serum selenium content were as follows: image 3 shown.

[0043] figure 1 Show, zinc-sel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

[Problem] To verify an advantage in terms of hepatic fibrosis-ameliorating effect in hepatitis / hepatic cirrhosis using a thioacetamide hepatic dysfunction model, and provide this advantage. [Solution] This advantage is achieved by means of a compounding agent that includes zinc and selenium.

Description

Background technique [0001] The present invention relates to nutritional functional foods and pharmaceuticals for improving liver fibrosis that accompanies the progression of chronic hepatitis to liver cirrhosis. It is a zinc-selenium complex, which shows advantages over the zinc preparation Polaprezinc (L-carnosine zincate). [0002] Chronic hepatitis can be roughly divided into two categories according to the cause of the disease. One type is viral chronic hepatitis caused by hepatitis virus. The other type is not infected with hepatitis virus, which is called chronic liver dysfunction. Viral chronic hepatitis is divided into chronic hepatitis B and chronic hepatitis C. Non-viral chronic hepatitis is divided into alcoholic hepatitis, autoimmune hepatitis, drug-induced hepatitis, fatty liver, toxic hepatitis and so on. [0003] These chronic hepatitis continue to develop and become cirrhosis of the liver. The pathological point of view is to cause the collapse of liver c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/00A61K33/30A61K33/04A61K47/02A61K47/22A61P1/16
CPCA61K33/04A61K33/30A61K47/02A61K47/22
Inventor 久保田悟河野透
Owner 谢灵均
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products